By Fineline Cube Jenscare Scientific Co., Ltd. (HKG: 9877) announced that its proprietary transvenous tricuspid valve replacement system, LuX-Valve Plus, has received European Union Medical Device Regulation (MDR) CE certification. The device represents the world’s second approved transcatheter in-situ tricuspid valve replacement product, featuring innovative design elements that address key clinical challenges in tricuspid regurgitation treatment.
Regulatory Milestone & Product Classification
| Item | Detail |
|---|---|
| Company | Jenscare Scientific Co., Ltd. (HKG: 9877) |
| Product | LuX-Valve Plus transvenous tricuspid valve replacement system |
| Regulatory Approval | EU MDR CE Certification |
| Classification | World’s second transcatheter in-situ tricuspid valve replacement |
| Approach | Transvascular (minimally invasive) |
| Size Range | Seven sizes (40mm to 70mm) |
| Announcement Date | 8 July 2026 |
Technology Innovation & Clinical Advantages
- Interventricular Septum Anchoring: Unlike conventional prosthetic valves that rely on radial force for fixation, LuX-Valve Plus employs a septal anchoring design that minimizes cardiac tissue damage and facilitates post-operative right ventricular remodeling, potentially improving long-term cardiac function.
- Reduced Pacemaker Risk: The non-radial force anchoring mechanism significantly reduces the risk of conduction disturbances requiring permanent pacemaker implantation—a common complication with traditional transcatheter valve technologies.
- Anti-Leak Technology: An adaptive anti-leak skirt effectively minimizes paravalvular leak, a critical factor in ensuring optimal hemodynamic performance and preventing recurrent tricuspid regurgitation.
- Precision Delivery System: A multi-dimensionally steerable delivery catheter enables precise valve positioning during deployment, crucial for successful outcomes in the anatomically complex tricuspid valve environment.
Tricuspid regurgitation affects approximately 1.6 million patients in Europe and over 3 million globally, with severe cases carrying poor prognosis and limited treatment options beyond high-risk surgical intervention.
Market Positioning & Competitive Landscape
Second-Mover Advantage: As the world’s second approved device in this emerging category, LuX-Valve Plus benefits from validated market demand while incorporating design improvements based on clinical experience with the first-generation technology.
Comprehensive Sizing: The availability of seven sizes (40-70mm) addresses the broad anatomical variability of tricuspid annuli, enabling treatment of a wider patient population compared to more limited sizing options in competing devices.
Minimally Invasive Approach: The transvascular delivery method eliminates the need for open-heart surgery or direct cardiac puncture, making the therapy accessible to high-risk and elderly patients who would otherwise be ineligible for surgical intervention.
Commercial Strategy & Global Expansion
- EU Market Entry: CE certification enables immediate commercial launch across all 27 EU member states plus associated countries, representing the world’s largest integrated medical device market.
- Reimbursement Pathway: The established precedent of the first approved device provides a clear pathway for hospital adoption and reimbursement coding, accelerating market penetration.
- Pipeline Validation: Success with LuX-Valve Plus validates Jenscare’s structural heart platform and supports development of additional transcatheter valve technologies for other cardiac indications.
Forward‑Looking Statements
This brief contains forward-looking information regarding regulatory approvals, market opportunities, and commercial strategies. Actual results may differ due to market adoption rates, competitive dynamics, reimbursement decisions, and clinical outcomes.-Fineline Info & Tech